螺内酯联合卡维地洛治疗难治性高血压的临床效果

Abstract
Figure/Table
References (15)
Related Citation (6)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Objective To investigate the clinical effect of Spironolactone combined with Carvedilol in the treatment of refractory hypertension.Methods A total of 80 patients with refractory hypertension admitted in our hospital from January 2017 to August 2018 were selected as the subjects,and randomly divided into routine group (n=40)and study group (n=40).Carvedilol was used in routine group.The study group was treated with Carvedilol combined with Spironolactone.The blood pressure,echocardiography and clinical efficacy were compared between the two groups.Results After treatment,the blood pressure of the two groups were significantly lower than those of the conventional group,and the blood pressure of the study group were significantly lower than that of the conventional group,with statistically significant differences(P<0.05).After treatment,the left ventricular ejection fraction of the two groups was higher than that before treatment,and the left ventricular ejection fraction of the study group was higher than that of the conventional group,with statistically significant differences(P<0.05).After treatment,the inner diameter at the end of left ventricular contraction was smaller than that before treatment in both groups,and the inner diameter at the end of left ventricular contraction in the study group was smaller than that of the conventional group,with statistically significant differences (P<0.05).The total effective rate of the study group was significantly higher than that of the conventional group (P<0.05).The total incidence of adverse reactions in the study group was lower than that in the conventional group,and the difference was statistically significant(P<0.05).Conclusion Spironolactone combined with Carvedilol is effective in the treatment of refractory hypertension.It can not only improve the blood pressure and echocardiographic parameters,but also reduce the incidence of adverse reactions.It is worth popularizing in this area.

Key words： Spironolactone Carvedilol Refractory hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I7/55

[1]	刘娟，刘海，汤永谦，等.美托洛尔和卡维地洛对肾血管性高血压的血压及心室重构的干预作用[J].河北医药，2018，40（15）：2245-2250.
[2]	温怿涛，郭予洁.卡维地洛治疗高血压合并糖尿病患者心律失常的评估[J].中国实用医药，2018，13（15）：118-120.
[3]	吴应强，陈小燕，谭先群.维地洛联合依拉普利治疗高血压心脏病的疗效[J].大医生，2018，3（5）：76-77.
[4]	卢丽华，廖通，李焕轮，等.螺内酯联合甲磺酸氨氯地平片治疗老年高血压心脏病的效果[J].中国当代医药，2018，25（13）：16-19.
[5]	李梦琦，路军，甘继宏.卡维地洛对低温应激高血压大鼠心肌内质网GRP78和CHOP的表达及心肌细胞凋亡的影响[J].海军医学杂志，2018，39（1）：29-32.
[6]	盛爱强.卡维地洛治疗高血压合并糖尿病患者心律失常的临床效果分析[J].中国处方药，2018，16（1）：99-100.
[7]	马晶晶.卡维地洛与美托洛尔对高血压的效果及对糖脂代谢的影响对比分析[J].世界最新医学信息文摘，2018，18（4）：89-90，96.
[8]	李彦影，葛欣.螺内酯联合卡维地洛治疗难治性高血压的临床分析[J].中国医药指南，2017，15（31）：183-184.
[9]	申庆荣，李刚.螺内酯治疗难治性高血压的研究进展[J].中国医院药学杂志，2016，36（23）：2126-2131.
[10]	余志国，鲍玉洁，丘军，等.卡维地洛联合螺内酯治疗高血压临床效果分析[J].中国实用医药，2016，11（18）：41-42.
[11]	刘芳.卡维地洛联合螺内酯治疗高血压的疗效观察[J].中国医药指南，2016，14（3）：190-191.
[12]	李可.螺内酯联合卡维地洛治疗难治性高血压的效果观察[J].中国医药指南，2016，14（2）：44-45.
[13]	盖延红，栾晓东，朱为勇，等.螺内酯治疗不同年龄难治性高血压的疗效差别[J].中国循证心血管医学杂志，2015，7（4）：537-538，541.
[14]	刘立立.卡维地洛联合螺内酯治疗难治性高血压的系统评价[A].//中华医学会、中华医学会临床药学分会.中华医学会临床药学分会2014年全国学术会议论文汇编[C].中华医学会、中华医学会临床药学分会，2014：1.
[15]	王有龙，李雪，赵媛.卡维地洛联合螺内酯治疗高血压的疗效观察[J].四川生理科学杂志，2015，36（1）：19-21.